Research programme: cell and gene therapies - Baylor College of Medicine/Cell Medica

Drug Profile

Research programme: cell and gene therapies - Baylor College of Medicine/Cell Medica

Alternative Names: CAR-modified NKT cell therapy; CMD 501; CMD 502; CMD 503; CMD 504; CMD 601; Off-the-shelf allogeneic cell therapy; Off-the-shelf allogeneic NKT; T-cell receptor therapy - Cell Medica/Baylor College of Medicine

Latest Information Update: 25 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baylor College of Medicine
  • Developer Cell Medica
  • Class Gene therapies; NKT cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 25 May 2018 Preclinical trials in Haematological malignancies in USA (Parenteral)
  • 25 May 2018 Preclinical trials in Solid tumours in USA (Parenteral)
  • 25 May 2018 Cell Medica plans a phase I/II trial of CMD 501 in Neuroblastoma in Q2-2018 (Cell Medica pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top